CVD risks in women living with HIV

CVD risks in women living with HIV

Hi there. My name is Chris Longenecker. I'm a cardiologist at the University of Washington in Seattle, Washington, USA. I specialize in the care of people living with HIV infection. For many years I've run a clinic focused on cardiovascular disease management and prevention of cardiovascular disease for people living with HIV, first in Cleveland, Ohio for many years and now in Seattle.
Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV

With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), is crucial. This strategy aims to reduce HIV transmission and control new infections. The 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland, from October 18 to 20, 2023. At the conference, Professor Jean-Michel Molina from the University of Paris City, Saint Louis and Lariboisière Hospital, shared insights on the application and challenges of HIV PrEP and PEP.

Progress and Challenges in the Field of HIV/AIDS – The 19th EACS Conference Concludes Successfully

The 19th European AIDS Conference (EACS 2023), a highly anticipated event in the field of HIV/AIDS, was held grandly in Warsaw, Poland, from October 18 to 20, 2023. The conference provided a robust platform for medical professionals and researchers in the HIV/AIDS field, facilitating a comprehensive and multi-faceted discussion on urgent issues in combating HIV/AIDS. It showcased numerous breakthrough clinical studies and honored outstanding contributors in the field. The conference offered a thorough and in-depth interpretation of the current status and future vision of global HIV/AIDS prevention and treatment.

What to start with? A review of current guidelines (EACS, WHO, DHHS)

Hello. My name is Cristiana Oprea. I'm an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also part of the EuroSida steering committee since 2017.

Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients

This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment of HIV does not increase the risk of cardiovascular events.
IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United States, Dr. Ryan K. Shields from the University of Pittsburgh presented a real-world observational study assessing the effectiveness of ceftolozane-tazobactam compared to ceftazidime-avibactam in treating multidrug-resistant Pseudomonas aeruginosa (MDR-PA). He shared his insights in an interview with " Infectious Disease Frontline".
Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Dr. Thomas L. Holland：Careful consideration when selecting clinical outcomes brings more possibilities to clinical trials of bacterial diseases

Staphylococcus aureus bacteremia is a major cause of bloodstream infections, and hospital-acquired bacterial pneumonia is often caused by multidrug-resistant bacteria. And developing new antibiotics requires patient-centered clinical outcomes. How to conduct a patient-centered benefit-risk assessment in the design, analysis, and interpretation of clinical trials, so that more bacterial clinical studies can achieve the expected efficacy? At the recently Infectious Disease Week (IDWeek 2023), "Infectious Disease Frontline" invited Dr. Thomas L. Holland from Duke University Medical Center to introduce the practical application and potential challenges of DOOR research on ordinal outcome, and shared its importance to future clinical trials and treatment plans.
IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship between intestinal colonization and infection of other MDROs remains to be clarified. In a recent oral presentation at the 2023 Infectious Diseases Week (IDWeek 2023), a researcher reported a study on the relationship between MDRO intestinal colonization and the risk of bloodstream infection (BSI). Dr. Yonghong Xiao, from the First Affiliated Hospital, Zhejiang University School of Medicine, provides an introduction and commentary on this research.
IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

In a special session titled "Clinical Trials That May Change Your Practice" at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of California Davis Medical Center presented a fascinating report on "Clinical Trials in Fungal Diseases That May Change Your Practice". He also granted an interview with "Infectious Disease Frontline"(IDF) after the conference.